Immunovaccine and Leidos are working together to determine the most promising malaria vaccine formulations.
Now that Prostvac has failed as a stand-alone therapy, Bavarian Nordic's MVA-BN RSV vaccine is now extra-important.
Three major regulatory bodies – FDA, EMA and Health Canada – changed their guidelines to drug naming. How could these changes impact drug launch timelines?
Here is some other vaccine news of note for the week.
Takeda's dengue vaccine induced sustained antibody responses in children, topline phase 2 data showed.
Aviragen and Vaxart merged into one company aimed at developing oral vaccines against flu, norovirus and RSV.
Here is some other vaccine news of note for this week.
China's FDA approved a domestically developed Ebola vaccine based on a different virus type from GSK's and Merck's shots.
No currently available vaccines against typhoid are meant for children younger than 2, but a new WHO endorsement could change that.
Young biotech Codagenix just secured $3 million in funding to advance its live-attenuated RSV vaccine candidate.
A large-scale phase 3 study shows that Merck's Gardasil 9 vaccine protects against HPV-related cancers for at least six years.